Scarica l'app Stockscreener
3.11
1.63%
0.05
Dopo l'orario di chiusura:
3.08
-0.03
-0.96%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RXRX Giù?
Forum
Previsione
Precedente Chiudi:
$3.06
Aprire:
$2.94
Volume 24 ore:
9.19M
Relative Volume:
0.50
Capitalizzazione di mercato:
$1.64B
Reddito:
$74.68M
Utile/perdita netta:
$-644.76M
Rapporto P/E:
-2.0972
EPS:
-1.4829
Flusso di cassa netto:
$-380.44M
1 W Prestazione:
-1.27%
1M Prestazione:
-14.33%
6M Prestazione:
-43.66%
1 anno Prestazione:
-41.21%
Intervallo 1D:
$2.93
$3.13
Intervallo di 1 settimana:
$2.80
$3.21
Portata 52W:
$2.80
$7.18
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Nome
Recursion Pharmaceuticals Inc
Settore
Industria
Telefono
(385) 269-0203
Indirizzo
41S RIO GRANDE STREET, SALT LAKE CITY
Compare RXRX vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
3.11 | 1.64B | 74.68M | -644.76M | -380.44M | -1.4829 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2025-07-03 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-05-22 | Iniziato | Morgan Stanley | Equal-Weight |
| 2023-03-16 | Iniziato | Needham | Buy |
| 2022-09-16 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-03-04 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | Iniziato | Berenberg | Buy |
| 2021-05-11 | Iniziato | BofA Securities | Buy |
| 2021-05-11 | Iniziato | Goldman | Neutral |
| 2021-05-11 | Iniziato | JP Morgan | Neutral |
| 2021-05-11 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Recursion Pharmaceuticals Inc Borsa (RXRX) Ultime notizie
Fund Flows: Is Recursion Pharmaceuticals Inc forming a double bottom2026 Snapshot & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Recursion Pharmaceuticals, Inc. (RXRX) latest stock news and headlines - au.finance.yahoo.com
Recursion Pharmaceuticals, Inc. (RXRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Recursion Pharmaceuticals, Inc. (RXRX) stock price, news, quote and history - Yahoo Finance Singapore
Does AI Data Deal And New CMO Hire Change The Bull Case For Recursion (RXRX)? - Sahm
Recursion Pharmaceuticals (RXRX) beats stock market upswing: What investors need to know - MSN
Recursion Pharmaceuticals (RXRX) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
Director at Recursion (NASDAQ: RXRX) awarded 3,268 shares - Stock Titan
RXRX Stock Price, Quote & Chart | RECURSION PHARMACEUTICALS-A (NASDAQ:RXRX) - ChartMill
A Look At Recursion Pharmaceuticals (RXRX) Valuation As Investor Narratives Diverge - Sahm
1 Beaten-Down AI Stock to Buy and 1 to Avoid - Yahoo Finance
Recursion names Vicki Goodman as CMO - MSN
Citeline expands partnership with Recursion for clinical trials - investing.com
Recursion Expands Strategic Partnership with Citeline to Advance Its AI-Enabled ClinTech Platform - GlobeNewswire Inc.
2 AI Healthcare Stocks to Buy Right Now - The Globe and Mail
Recursion Pharmaceuticals (RXRX) down 16.5% since last earnings report: Can it rebound? - MSN
RXRX SEC FilingsRecursion Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Recursion Pharmaceuticals (RXRX) Surges 14% Ahead of Earnings - MSN
Recursion Pharmaceuticals (NASDAQ:RXRX) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Recursion Pharmaceuticals stock hits 52-week low at $2.98 By Investing.com - Investing.com Australia
Here's Why Recursion Pharmaceuticals (RXRX) Fell More Than Broader Market - Yahoo Finance
Recursion Pharmaceuticals | SCHEDULE 13G/A: Others - Moomoo
RXRX Faces Stock Strain as Bank of America Slashes Price Target - StocksToTrade
Recursion Pharmaceuticals (NASDAQ:RXRX) Reaches New 52-Week LowWhat's Next? - MarketBeat
Recursion Pharmaceuticals (RXRX) Has Fallen 16.5% Since Previous Earnings Report: Is a Recovery Possible? - Bitget
Recursion Pharmaceuticals (RXRX) Down 16.5% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Recursion Pharmaceuticals stock hits 52-week low at $2.98 - Investing.com
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Vanguard disaggregates holdings; (RXRX) Schedule 13G/A shows 0 shares - Stock Titan
RXRX Stock: Why Did Nvidia Offload AI Drug Developer Recursion? - cmcmarkets.com
New Recursion CMO Puts Oncology Experience At Center Of Investor Focus - Sahm
Assessing Recursion Pharmaceuticals (RXRX) Valuation After Recent Share Price Weakness And Split Fair Value Views - Yahoo Finance
Recursion Pharmaceuticals Appoints Vicki Goodman, M.D. as Chief Medical Officer to Advance Clinical Pipeline and AI-Driven Drug Development 1 - Minichart
Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Gibson Christopher - Moomoo
Recursion Pharmaceuticals Names New Chief Medical Officer - TipRanks
Recursion appoints Vicki Goodman as Chief Medical Officer; David Mauro to transition to advisor - tradingview.com
Vicki Goodman to become Recursion (NASDAQ: RXRX) chief medical officer - Stock Titan
[Form 4] RECURSION PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Recursion Pharmaceuticals (RXRX) Goldman Sachs 45th Annual Global Healthcare Conference summary - Quartr
EXEL: Former Executive Joins Recursion Pharmaceuticals as New CM - GuruFocus
Recursion Announces Vicki Goodman, M.D., as Incoming Chief Medical Officer - marketscreener.com
Recursion taps former FDA reviewer Vicki Goodman as chief medical officer - Stock Titan
Assessing Recursion Pharmaceuticals (RXRX) Valuation After Prolonged Share Price Weakness - sahmcapital.com
Recursion Pharmaceuticals Stock (RXRX) Opinions on Roche's AI Drug Development Commitment - Quiver Quantitative
Recursion Pharmaceuticals Inc Azioni (RXRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):